{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:14:30Z","timestamp":1780640070969,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/0-149-03\/503-01-001-19-00"],"award-info":[{"award-number":["503\/0-149-03\/503-01-001-19-00"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>New vaccines are being developed to fight the ongoing COVID-19 pandemic. In our study we compared the efficacy of COVID-19 vaccines to prevent COVID-19-related infections and mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>17 randomized clinical trials of COVID-19 vaccines were included after search in databases. We compared COVID-19 vaccines based on symptomatic and severe infections, number of deaths and hospitalizations related to COVID-19. Also, we analyzed the efficacy of COVID-19 against different variants of SARS-CoV-2 as well as according to different age groups. Random effects model using Mantel\u2013Haenzeal method was used to pool relative risk (RR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our meta-analysis shows that full vaccination could decrease not only the risk of symptomatic or severe COVID-19, the risk of hospitalization and death caused by COVID-19. COVID-19 vaccines were also effective against variants of SARS-CoV-2 (RR\u2009=\u20090.36; 95% CI [0.25; 0.53], p\u2009&lt;\u20090.0001). However, efficacy of vaccination varied in COVID-19 variant-dependent manner. Moreover, the analysis in different age groups showed that COVID-19 vaccines had the similar results: the risk was slightly lower in adults compared to elderly cohort <jats:inline-formula><jats:alternatives><jats:tex-math>$$(\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mrow>\n                      <mml:mo>(<\/mml:mo>\n                      <mml:mo>\u2265<\/mml:mo>\n                    <\/mml:mrow>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 65\u00a0years): (RR\u2009=\u20090.16, 95% CI [0.11; 0.23]) and (RR\u2009=\u20090.19, 95% CI [0.12; 0.30]), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Data obtained from clinical trials of COVID-19 vaccines looks promising, in order to fully investigate efficacy of the vaccines further clinical examination is required especially considering new SARS-CoV-2 variants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-022-00525-3","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T10:02:32Z","timestamp":1656842552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-7730","authenticated-orcid":false,"given":"Marharyta","family":"Sobczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-453X","authenticated-orcid":false,"given":"Rafa\u0142","family":"Pawliczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"key":"525_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.csbj.2020.12.033","volume":"19","author":"MF ur Rehman","year":"2020","unstructured":"ur Rehman MF, Fariha C, Anwar A, Shahzad N, Ahmad M, Mukhtar S, et al. Novel coronavirus disease (COVID-19) pandemic: a recent mini review. Comput Struct Biotechnol J. 2020;19:612\u201323.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10","key":"525_CR2","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/ijbs.45053","volume":"16","author":"J Zheng","year":"2020","unstructured":"Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678\u201385.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"525_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"525_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0145561320920762","volume":"99","author":"A Lovato","year":"2020","unstructured":"Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569\u201376.","journal-title":"Ear Nose Throat J"},{"issue":"109","key":"525_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102433","volume":"1","author":"HA Rothan","year":"2020","unstructured":"Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;1(109): 102433.","journal-title":"J Autoimmun"},{"issue":"40","key":"525_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101129","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;12(40): 101129.","journal-title":"EClinicalMedicine"},{"key":"525_CR7","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int. Accessed 4 Dec 2021."},{"issue":"4","key":"525_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000514225","volume":"182","author":"Z Strizova","year":"2021","unstructured":"Strizova Z, Smetanova J, Bartunkova J, Milota T. Principles and challenges in anti-COVID-19 vaccine development. Int Arch Allergy Immunol. 2021;182(4):339\u201349.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"525_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/ph14050406","volume":"14","author":"Z-P Yan","year":"2021","unstructured":"Yan Z-P, Yang M, Lai C-L. COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals. 2021;14(5):406.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"525_CR10","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","volume":"21","author":"SH Hodgson","year":"2021","unstructured":"Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26-35.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"525_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"issue":"oct18 2","key":"525_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928\u2013d5928.","journal-title":"BMJ"},{"key":"525_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/9780470712184.ch9","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JJ Deeks","year":"2008","unstructured":"Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 243\u201396."},{"issue":"27","key":"525_CR14","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"525_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"key":"525_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017","author":"HM El Sahly","year":"2021","unstructured":"El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2113017.","journal-title":"N Engl J Med"},{"key":"525_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109522","author":"K Ali","year":"2021","unstructured":"Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2109522.","journal-title":"N Engl J Med"},{"key":"525_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2110345.","journal-title":"N Engl J Med"},{"key":"525_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456","author":"RW Frenck","year":"2021","unstructured":"Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107456.","journal-title":"N Engl J Med"},{"issue":"10275","key":"525_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671\u201381.","journal-title":"Lancet"},{"key":"525_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2101544.","journal-title":"N Engl J Med"},{"issue":"20","key":"525_CR22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885\u201398.","journal-title":"N Engl J Med"},{"issue":"12","key":"525_CR23","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1038\/s41467-021-25982-w","volume":"6","author":"SAC Clemens","year":"2021","unstructured":"Clemens SAC, Folegatti PM, Emary KRW, Weckx LY, Ratcliff J, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nat Commun. 2021;6(12):5861.","journal-title":"Nat Commun"},{"key":"525_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2105290.","journal-title":"N Engl J Med"},{"issue":"10269","key":"525_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"20","key":"525_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B1351 variant. N Engl J Med. 2021;384(20):1899\u2013909.","journal-title":"N Engl J Med"},{"key":"525_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107659.","journal-title":"N Engl J Med"},{"issue":"1","key":"525_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35\u201345.","journal-title":"JAMA"},{"issue":"44","key":"525_CR29","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","volume":"39","author":"E Fadlyana","year":"2021","unstructured":"Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):6520\u20138.","journal-title":"Vaccine"},{"issue":"10296","key":"525_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213\u201322.","journal-title":"Lancet"},{"key":"525_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01446-y","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021. https:\/\/doi.org\/10.1038\/s41591-021-01446-y.","journal-title":"Nat Med"},{"issue":"11","key":"525_CR32","doi-asserted-by":"publisher","first-page":"1699.e5","DOI":"10.1016\/j.cmi.2021.06.043","volume":"27","author":"C Paris","year":"2021","unstructured":"Paris C, Perrin S, Hamonic S, Bourget B, Rou\u00e9 C, Brassard O, et al. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. Clin Microbiol Infect. 2021;27(11):1699.e5-1699.e8.","journal-title":"Clin Microbiol Infect"},{"issue":"373","key":"525_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088","volume":"13","author":"JL Bernal","year":"2021","unstructured":"Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case\u2013control study. BMJ. 2021;13(373): n1088.","journal-title":"BMJ"},{"issue":"15","key":"525_CR34","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"525_CR35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10787-021-00839-2","volume":"29","author":"CS Kow","year":"2021","unstructured":"Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacol. 2021;29(4):1075\u201390.","journal-title":"Inflammopharmacol"},{"issue":"12","key":"525_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","volume":"11","author":"N Sharif","year":"2021","unstructured":"Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;11(12): 714170.","journal-title":"Front Immunol"},{"issue":"11","key":"525_CR37","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","volume":"23","author":"V Rotshild","year":"2021","unstructured":"Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;23(11):22777.","journal-title":"Sci Rep"},{"issue":"1","key":"525_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00336-1","volume":"6","author":"I McDonald","year":"2021","unstructured":"McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines. 2021;6(1):1\u201314.","journal-title":"npj Vaccines"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-022-00525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T10:02:36Z","timestamp":1656842556000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-022-00525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s12941-022-00525-3","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}